We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Gemphire Therapeutics Inc | NASDAQ:GEMP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.30 | 0.30 | 0.3169 | 0 | 01:00:00 |
What: Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company that is developing and commercializing therapies to help patients with cardiometabolic disorders, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Dr. Charles Bisgaier, Chairman & CSO / Co-Founder, will ring the Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:Tuesday, August 8, 2017 – 3:45 p.m. to 4:00 p.m. ET
Gemphire Therapeutics Inc. Contact:Jeff Mathiesen(734) 245-1700jmathiesen@gemphire.com
Nasdaq MarketSite:Emily Pan(646) 441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Gemphire Therapeutics Inc.Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has initiated 3 clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH to initiate in second half of 2017. Please visit www.gemphire.com for more information.
About Nasdaq:Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
-NDAQA-
1 Year Gemphire Therapeutics Chart |
1 Month Gemphire Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions